|
|
Pacira Biosciences inc (PCRX) |
|
|
|
| |
PCRX's Net Income Growth by Quarter and Year
Pacira Biosciences Inc 's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| PCRX Net Income (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
-
|
10.86
|
-0.69
|
17.66
|
| III Quarter |
September |
-
|
25.76
|
19.88
|
19.08
|
| II Quarter |
June |
18.89
|
-19.54
|
6.83
|
10.37
|
| I Quarter |
March |
8.98
|
-10.10
|
-5.13
|
130.12
|
| FY |
|
27.87
|
6.98
|
20.89
|
177.23
|
| PCRX Net Income second quarter 2024 Y/Y Growth Comment |
Pacira Biosciences inc in the second quarter 2024 achieved Net Income of $ 18.89 millions compare to net loss recorded in same quarter a year ago.
According to the results reported in the second quarter 2024, Pacira Biosciences Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Pacira Biosciences Inc ' s Net Income no change of % ranks overall at the positon no. 11 in the second quarter 2024.
|
| PCRX Net Income ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
- |
- |
- |
| III Quarter |
September |
- |
29.58 % |
4.19 % |
133.82 % |
| II Quarter |
June |
- |
- |
-34.14 % |
- |
| I Quarter |
March |
- |
- |
- |
- |
| FY |
|
- |
-66.59 % |
-88.21 % |
- |
PCRX Net Income (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
-57.84 % |
- |
-7.44 % |
| III Quarter |
September |
- |
- |
191.07 % |
83.99 % |
| II Quarter |
June |
110.31 % |
- |
- |
-92.03 % |
| I Quarter |
March |
-17.31 % |
- |
- |
- |
| FY (Year on Year) |
|
- |
-66.59 % |
-88.21 % |
- |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1283.82 % |
-177.59 % |
-2144.67 % |
| (Sep 30 2020) |
|
(Dec 31 2016) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1283.82 % |
-177.59 % |
-2144.67 % |
| (Sep 30 2020) |
|
(Dec 31 2016) |
|
| Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Pacira Biosciences Inc 's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 38475 % |
4827.19 % |
-99.37 % |
| (Sep 30 2015) |
|
|
| PCRX's II. Quarter Q/Q Net Income Comment |
Pacira Biosciences inc achieved in the II. Quarter 2024 below company average Net Income doubling of 110.31% quarter on quarter, to $ 18.89 millions.
Albeit the II. Quarter 2024 Net Income sequential growth was beneath the regular of 4827.19 %, that was still encouraging news, as the II. Quarter expension, eclipses the % Net Income surge in the same quarter a year ago
Within Major Pharmaceutical Preparations industry Pacira Biosciences inc achieved highest sequential Net Income growth. While Pacira Biosciences Inc 's Net Income growth quarter on quarter, overall rank is 37. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 38475 % |
4827.19 % |
-99.37 % |
| (Sep 30 2015) |
|
|
| PCRX's II. Quarter Q/Q Net Income Comment |
Pacira Biosciences inc achieved in the II. Quarter 2024 below company average Net Income doubling of 110.31% quarter on quarter, to $ 18.89 millions.
Even if the II. Quarter 2024 PCRX's results were below the regular , it has been yet promising story, as the II. Quarter improvement, eclipses the % Net Income rise in the same quarter a year ago
Within Major Pharmaceutical Preparations industry Pacira Biosciences inc achieved highest sequential Net Income growth. While Pacira Biosciences Inc 's Net Income growth quarter on quarter, overall rank is 37. |
|
Pacira Biosciences Inc 's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Sep 30 2023) |
12 Months Ending
(Jun 30 2023) |
12 Months Ending
(Mar 31 2023) |
| Cumulative Net Income 12 Months Ending |
$ 64.49 |
$ 26.06 |
$ 6.98 |
$ -4.57 |
$ -10.46 |
| Y / Y Net Income Growth (TTM) |
- |
63.83 % |
-66.56 % |
- |
- |
| Year on Year Net Income Growth Overall
Ranking |
# 324 |
# 1286 |
# 1466 |
# 1762 |
# 1628 |
| Seqeuential Net Income Change (TTM) |
147.41 % |
273.25 % |
- |
- |
- |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 11 |
# 973 |
# 746 |
# 1039 |
# 1050 |
| Cumulative Net Income growth
Comment |
In the Jun 30 2024 period, Pacira Biosciences Inc had cumulative twelve months Net Income of $ 64 millions compare to net loss of $ -10 millions a year ago.
Even more so, not just that Pacira Biosciences Inc has returned to profitability, it by this time is heading full steam and recording above usual Net Income surge, from the twelve months ending in the quarter Mar 31 2024 of 147.41 % from $26.06 millions.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 324, from total ranking in previous quarter at 1286. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1283.82 % |
-177.59 % |
-2144.67 % |
|
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1283.82 % |
-177.59 % |
-2144.67 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 2 |
| S&P 500 |
# 11 |
|
| Cumulative Net Income growth
Comment |
In the Jun 30 2024 period, Pacira Biosciences Inc had cumulative twelve months Net Income of $ 64 millions compare to net loss of $ -10 millions a year ago.
Even more so, not just that PCRX has regained the bottom-line, the company is, as of now gaining momentum and showing above usual Net Income rise, from the twelve months ending in the quarter Mar 31 2024 of 147.41 % from $26.06 millions.
Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 324, from total ranking in previous quarter at 1286. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1283.82 % |
-177.59 % |
-2144.67 % |
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1283.82 % |
-177.59 % |
-2144.67 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 2 |
| S&P 500 |
# 11 |
|
